HIV-1感染是危害全球公共卫生健康的严重问题。随着抗体技术的不断进步，一些抗HIV单克隆抗体在临床试验中取得了较好的结果，第一个用于治疗HIV感染的单克隆抗体药物Ibalizumab也已上市。针对HIV的双特异性抗体和多特异性抗体的研发也取得了较大进展，但同时也面临挑战。

 HIV-1 infection is a serious problem endangering global public health. With the continuous progress of antibody technology, many anti-HIV monoclonal antibodies have shown satisfying outcome in clinical trials, The first monoclonal antibody drug for HIV-infection treatment, Ibalizumab,has come onto market. In addition, the research and development of bi-specific and multi-specific antibodies against HIV has also made great progress, but also facing some challenges